240 related articles for article (PubMed ID: 36739065)
21. Potential Role of microRNAs in inducing Drug Resistance in Patients with Multiple Myeloma.
Allegra A; Ettari R; Innao V; Bitto A
Cells; 2021 Feb; 10(2):. PubMed ID: 33672466
[TBL] [Abstract][Full Text] [Related]
22. 3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma.
de la Puente P; Muz B; Gilson RC; Azab F; Luderer M; King J; Achilefu S; Vij R; Azab AK
Biomaterials; 2015 Dec; 73():70-84. PubMed ID: 26402156
[TBL] [Abstract][Full Text] [Related]
23. RNA interference for multiple myeloma therapy: targeting signal transduction pathways.
Guo J; McKenna SL; O'Dwyer ME; Cahill MR; O'Driscoll CM
Expert Opin Ther Targets; 2016; 20(1):107-21. PubMed ID: 26190583
[TBL] [Abstract][Full Text] [Related]
24. Roles of miRNA dysregulation in the pathogenesis of multiple myeloma.
Chen D; Yang X; Liu M; Zhang Z; Xing E
Cancer Gene Ther; 2021 Dec; 28(12):1256-1268. PubMed ID: 33402729
[TBL] [Abstract][Full Text] [Related]
25. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
26. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.
Hideshima T; Mitsiades C; Tonon G; Richardson PG; Anderson KC
Nat Rev Cancer; 2007 Aug; 7(8):585-98. PubMed ID: 17646864
[TBL] [Abstract][Full Text] [Related]
27. Predicting the impact of combined therapies on myeloma cell growth using a hybrid multi-scale agent-based model.
Ji Z; Su J; Wu D; Peng H; Zhao W; Nlong Zhao B; Zhou X
Oncotarget; 2017 Jan; 8(5):7647-7665. PubMed ID: 28032590
[TBL] [Abstract][Full Text] [Related]
28. Exosomal microRNAs and long noncoding RNAs: Novel mediators of drug resistance in lung cancer.
Taghvimi S; Vakili O; Soltani Fard E; Khatami SH; Karami N; Taheri-Anganeh M; Salehi M; Negahdari B; Ghasemi H; Movahedpour A
J Cell Physiol; 2022 Apr; 237(4):2095-2106. PubMed ID: 35128660
[TBL] [Abstract][Full Text] [Related]
29. [Latest Findings on the Mechanism of the Interaction Between Multiple Myeloma Cells and Bone Marrow Microenvironment].
He NH; Zhou W
Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 May; 54(3):475-481. PubMed ID: 37248571
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA Transfer Between Bone Marrow Adipose and Multiple Myeloma Cells.
Soley L; Falank C; Reagan MR
Curr Osteoporos Rep; 2017 Jun; 15(3):162-170. PubMed ID: 28432594
[TBL] [Abstract][Full Text] [Related]
31. Tumor-host cell interactions in the bone disease of myeloma.
Fowler JA; Edwards CM; Croucher PI
Bone; 2011 Jan; 48(1):121-8. PubMed ID: 20615487
[TBL] [Abstract][Full Text] [Related]
32. Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment.
Corso A; Ferretti E; Lazzarino M
Hematology; 2005 Jun; 10(3):215-24. PubMed ID: 16019470
[TBL] [Abstract][Full Text] [Related]
33. Microenvironment drug resistance in multiple myeloma: emerging new players.
Di Marzo L; Desantis V; Solimando AG; Ruggieri S; Annese T; Nico B; Fumarulo R; Vacca A; Frassanito MA
Oncotarget; 2016 Sep; 7(37):60698-60711. PubMed ID: 27474171
[TBL] [Abstract][Full Text] [Related]
34. Targeting SDF-1 in multiple myeloma tumor microenvironment.
Bouyssou JM; Ghobrial IM; Roccaro AM
Cancer Lett; 2016 Sep; 380(1):315-8. PubMed ID: 26655999
[TBL] [Abstract][Full Text] [Related]
35. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
Podar K; Jager D
Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
[TBL] [Abstract][Full Text] [Related]
36. The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment.
Fan F; Bashari MH; Morelli E; Tonon G; Malvestiti S; Vallet S; Jarahian M; Seckinger A; Hose D; Bakiri L; Sun C; Hu Y; Ball CR; Glimm H; Sattler M; Goldschmidt H; Wagner EF; Tassone P; Jaeger D; Podar K
Leukemia; 2017 Jul; 31(7):1570-1581. PubMed ID: 27890927
[TBL] [Abstract][Full Text] [Related]
37. The WNT receptor ROR2 drives the interaction of multiple myeloma cells with the microenvironment through AKT activation.
Frenquelli M; Caridi N; Antonini E; Storti F; Viganò V; Gaviraghi M; Occhionorelli M; Bianchessi S; Bongiovanni L; Spinelli A; Marcatti M; Belloni D; Ferrero E; Karki S; Brambilla P; Martinelli-Boneschi F; Colla S; Ponzoni M; DePinho RA; Tonon G
Leukemia; 2020 Jan; 34(1):257-270. PubMed ID: 31148590
[TBL] [Abstract][Full Text] [Related]
38. The Role of Intracellular Signaling Pathways in the Pathogenesis of Multiple Myeloma and Novel Therapeutic Approaches.
Kizaki M; Tabayashi T
J Clin Exp Hematop; 2016; 56(1):20-7. PubMed ID: 27334854
[TBL] [Abstract][Full Text] [Related]
39. N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation.
Groen RW; de Rooij MF; Kocemba KA; Reijmers RM; de Haan-Kramer A; Overdijk MB; Aalders L; Rozemuller H; Martens AC; Bergsagel PL; Kersten MJ; Pals ST; Spaargaren M
Haematologica; 2011 Nov; 96(11):1653-61. PubMed ID: 21828122
[TBL] [Abstract][Full Text] [Related]
40. Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment.
Ho M; Xiao A; Yi D; Zanwar S; Bianchi G
Curr Oncol; 2022 Nov; 29(11):8975-9005. PubMed ID: 36421358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
